Articles: chronic.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: QVA149 is a once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary disease (COPD). The BEACON study evaluated the efficacy and safety of QVA149 compared with the concurrent administration of indacaterol and glycopyrronium (IND+GLY). ⋯ The study demonstrated that QVA149 provides benefits of dual bronchodilation in a single inhaler device, making it a more convenient treatment option for patients with moderate-to-severe COPDDISCLOSURE: Ronald Dahl: Consultant fee, speaker bureau, advisory committee, etc.: In the past 3 years, Professor Dahl has received compensation for consulting with Boehringer-Ingelheim, Novartis, Vectura, Roche, Elevation Pharma and Norpharma; has undertaken research funded by AstraZeneca, Boehringer- Ingelheim, C hiesi, GlaxoSmithKline, Novartis, ALK-Abello and Stallergenes; has participated in educational activities sponsored by AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, ALK-Abello, Novartis, Almirall. Dalal Jadayel: Employee: Novartis Employee Vijay Alagappan: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Bronchiectasis PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Bronchiectasis are defined as permanent, abnormal dilation of bronchi and bronchioles. Laenec in 1819, the first described them as a very common disease before the age of antibiotics. Today is a minor problem in developed countries in opposition to developing countries. The purpose of this study is to determine the prevalence of bacteria in patients with non-CF bronquiectacias. ⋯ The following authors have nothing to disclose: Georgina Gramblicka, Daniela Visentini, Valeria Morandi, Maria Laura Grodnitzky, Gabriela Tabaj, Patricia Malamud, Ana Sangoy, Andrea Appendino, Laura Biglieri, Silvia GuaycocheaNo Product/Research Disclosure Information.
-
Slide PresentationsPRESENTED ON: Monday, March 24, 2014 at 09:00 AM - 10:00 AMPURPOSE: Little is known about hospital readmission among patients <65 years hospitalized with Chronic Obstructive Pulmonary Disease (COPD). We aimed to determine the frequency and predictors of early readmission (within 30 days of discharge) among this population. ⋯ The following authors have nothing to disclose: Roozbeh Sharif, Trisha Parekh, Yong-Fang Kuo, Gulshan SharmaNo Product/Research Disclosure Information.
-
Infectious Disease Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: The etiology of bronchiectasis is varied with abnormal host defenses being one of the causes. We report the case of a 49-year-old male presenting with recurrent pneumonias. Imaging studies revealed bronchiectasis. Work up for bronchiectasis showed low immunoglobulin levels consistent with common variable immunodeficiency (CVID). The aim of this case report is to heighten awareness among physicians for the possibility of immunoglobulin deficiency in patients presenting especially with bronchiectasis, recurrent infections and sinus disease. ⋯ Among the various etiologies of bronchiectasis, the potentially treatable ones like CVID should never be missed. Appropriate and early institution of treatment can potentially improve survival, prevent deterioration of lung function and improve quality of life.Reference #1: Busse PJ, Farzan S, Cunningham-Rundles C, "Pulmonary complications of common variable immunodeficiency" Ann Allergy Asthma Immunol. 2007;98(1):1Reference #2: Park JH, Levinson AI,"Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID)" Clin Immunol. 2010;134(2):97DISCLOSURE: The following authors have nothing to disclose: Khalid Sherani, Hineshkumar Upadhyay, Abhay Vakil, Kelly Cervellione, Craig ThurmNo Product/Research Disclosure Information.
-
Cardiovascular Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Atrio-esophageal fistula is a fatal complication of radiofrequency ablation, which is associated with 80% mortality rate. Incidence rate for atrio-esophageal fistula formation is reported to be less than 1%. Dissemination of the organisms from the gut into the vasculature is the major cause of mortality. Hence, early diagnosis and immediate surgical intervention is necessary. Here we present a case of atrio-esophageal fistula occurred as a complication of radiofrequency ablation, complicated with sepsis and embolic stroke. ⋯ Given the associated poor prognosis, prompt recognition and emergent intervention are mandatory to decrease the mortality.Reference #1: Dagres N, Hindricks G, Kottkamp H, et al. Complications of atrial fibrillation ablation in a high-volume center in 1,000 procedures: still cause for concern? J Cardiovasc Electrophysiol 2009; 20:1014-Reference #2: Cappato R, Calkins H, Chen SA, et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 2009; 53:1798-803.Reference #3: Damian Sanchez-Quintana, Jose Angel Cabrera, Vicente Climent. Anatomic Relations Between The Esophagus and Left Atrium and Relevance for Ablation of Atrial Fibrillation.Circulation. 8/29/2005DISCLOSURE: The following authors have nothing to disclose: Sravanthi NandavaramNo Product/Research Disclosure Information.